Palbociclib

When it comes to naming children — at least in my generation — it was pretty straightforward.

In this episode, data show ‘critical need’ for universal genetic testing; patients with inflammatory breast cancer at high risk for brain metastases; palbociclib fails to benefit breast cancer subgroup and more.

Adjuvant palbociclib combined with endocrine therapy failed to extend invasive DFS compared with endocrine therapy alone among patients with stage IIA hormone receptor-positive, HER2-negative breast cancer, according to study results.

In this video, Kevin Kalinsky, MD, discussed new data on antibody-drug conjugates, including sacituzumab, presented at 39th Miami Breast Cancer Conference.

In this video, Payal Shah, MD, assistant professor of medicine at the hospital of the University of Pennsylvania, spoke with Healio about the ongoing HOPE trial.

In this video, Angela DeMichele, MD, MSCE, co-leader of the Breast Cancer Research Program and director of the Breast Cancer Clinical Trials Unit at Penn Medicine, discusses results from the PALLAS trial assessing palbociclib in early breast cancer.

In this video, Susan M. Domchek, MD, executive director of the Basser Center for BRCA and the director of the MacDonald Cancer Risk Evaluation Center at Penn Medicine, spoke with Healio about highlights from the San Antonia Breast Cancer Symposium.

The addition of palbociclib to endocrine therapy prolonged survival for Black and Hispanic women with hormone receptor-positive, HER2-negative metastatic breast cancer, according to results presented at San Antonio Breast Cancer Symposium.

In this video, Payal Shah, MD, assistant professor of medicine at the hospital of the University of Pennsylvania, discusses some of the highlights in hormone receptor-positive breast cancer presented at this year’s San Antonio Breast Cancer Symposium.

The addition of palbociclib to adjuvant endocrine therapy did not extend invasive DFS for patients with early hormone receptor-positive, HER2-negative breast cancer, according to results presented at San Antonio Breast Cancer Symposium.